Table 4– Baseline and end of study period values, and change from baseline to end of study period in vital sign parameters (safety set)

Vital signs parameter^#	Baseline		End of study period		Change from baseline to end of study period
Vital signs parameter^#	Placebo	Selexipag	Placebo	Selexipag	Placebo	Selexipag
Subjects n	10	33	10	33	10	33
Systolic blood pressure mmHg	116.2±11.7	117.3±18.5	112.7±17.3	114.0±15.8	−3.5±17.1	−3.6±17.3
Diastolic blood pressure mmHg	66.8±10.4	65.9±10.9	70.0±9.8	71.8±9.1	3.2±12.8	5.4±11.2
Heart rate beats·min⁻¹	74.8±13.2	75.3±15.8	77.9±10.5	75.2±12.1	3.1±6.0	−0.1±7.7

Data are presented as mean±sd. ^#: Treatment effect was not calculated for these safety parameters.